Share-based Payment Arrangement, Expense in USD of Ernexa Therapeutics Inc. from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ernexa Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2012 to Q3 2025.
  • Ernexa Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $293K, a 27.7% decline year-over-year.
  • Ernexa Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $1.57M, a 23.4% increase year-over-year.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1.52M, a 22.4% increase from 2023.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.24M, a 57.7% decline from 2022.
  • Ernexa Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.94M, a 43.9% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Ernexa Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.57M $293K -$112K -27.7% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-07
Q2 2025 $1.69M $368K -$55K -13% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 $1.74M $502K +$220K +78% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 $1.52M $410K +$245K +148% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-12
Q3 2024 $1.28M $405K +$231K +133% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-07
Q2 2024 $1.04M $423K +$209K +97.7% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 $835K $282K -$407K -59.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 $1.24M $165K -$232K -58.4% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-12
Q3 2023 $1.47M $174K -$302K -63.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $1.78M $214K -$665K -75.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $2.44M $689K -$494K -41.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $2.94M $397K -$1.79M -81.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $4.72M $476K -$1.25M -72.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $5.97M $879K -$275K -23.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $6.25M $1.18M +$1.01M +600% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $5.24M $2.18M +$2.16M +9475% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 $3.07M $1.73M +$1.71M +7505% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $1.37M $1.15M +$1.13M +4976% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $237K $169K +$146K +643% Jan 1, 2021 Mar 31, 2021 10-Q 2021-05-17
Q4 2020 $91K $22.8K Oct 1, 2020 Dec 31, 2020 10-K/A 2022-07-01
Q3 2020 $22.7K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $22.7K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $22.7K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q1 2015 $99K +$47K +90.4% Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-08
Q1 2014 $52K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08

Ernexa Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1.52M +$278K +22.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-12
2023 $1.24M -$1.69M -57.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-12
2022 $2.94M -$2.3M -43.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $5.24M +$5.14M +5653% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-20
2020 $91K Jan 1, 2020 Dec 31, 2020 10-K/A 2022-07-01
2013 $132K -$53K -28.6% Jan 1, 2013 Dec 31, 2013 10-K 2014-03-31
2012 $185K Jan 1, 2012 Dec 31, 2012 10-K 2014-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.